University of Oulu

Uzieliene I, Kalvaityte U, Bernotiene E and Mobasheri A (2021) Non-viral Gene Therapy for Osteoarthritis. Front. Bioeng. Biotechnol. 8:618399. doi: 10.3389/fbioe.2020.618399

Non-viral gene therapy for osteoarthritis

Saved in:
Author: Uzieliene, Ilona1; Kalvaityte, Ursule1; Bernotiene, Eiva1;
Organizations: 1Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
2Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
3Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
4Centre for Sport, Exercise and Osteoarthritis Versus Arthritis, Queen's Medical Centre, Nottingham, United Kingdom
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.8 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe202103298733
Language: English
Published: Frontiers Media, 2021
Publish Date: 2021-03-29
Description:

Abstract

Strategies for delivering nucleic acids into damaged and diseased tissues have been divided into two major areas: viral and non-viral gene therapy. In this mini-review article we discuss the application of gene therapy for the treatment of osteoarthritis (OA), one of the most common forms of arthritis. We focus primarily on non-viral gene therapy and cell therapy. We briefly discuss the advantages and disadvantages of viral and non-viral gene therapy and review the nucleic acid transfer systems that have been used for gene delivery into articular chondrocytes in cartilage from the synovial joint. Although viral gene delivery has been more popular due to its reported efficiency, significant effort has gone into enhancing the transfection efficiency of non-viral delivery, making non-viral approaches promising tools for further application in basic, translational and clinical studies on OA. Non-viral gene delivery technologies have the potential to transform the future development of disease-modifying therapeutics for OA and related osteoarticular disorders. However, further research is needed to optimize transfection efficiency, longevity and duration of gene expression.

see all

Series: Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
ISSN-E: 2296-4185
ISSN-L: 2296-4185
Volume: 8
Article number: 618399
DOI: 10.3389/fbioe.2020.618399
OADOI: https://oadoi.org/10.3389/fbioe.2020.618399
Type of Publication: A2 Review article in a scientific journal
Field of Science: 3126 Surgery, anesthesiology, intensive care, radiology
Subjects:
Funding: AM has received funding from the following sources: The European Commission Framework 7 programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815; Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases). The Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115770, resources of which are composed of financial contribution from the European Union's Seventh Framework programme (FP7/2007-2013) and EFPIA companies in-kind contribution. AM acknowledges funding from the European Commission through a Marie Curie Intra-European Fellowship for Career Development grant (project number 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF). The authors also acknowledge financial support from the European Structural and Social Funds (ES Strukturines Paramos) through the Research Council of Lithuania (Lietuvos Mokslo Taryba) according to the activity Improvement of researchers qualification by implementing world-class R&D projects of Measure No. 09.3.3-LMT-K-712 (grant application code: 09.3.3-LMT-K-712-01-0157, agreement No. DOTSUT-215) and the new funding programme: Attracting Foreign Researchers for Research Implementation (2018-2022), Grant No 01.2.2-LMT-K-718-02-0022.
Copyright information: © 2021 Uzieliene, Kalvaityte, Bernotiene and Mobasheri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
  https://creativecommons.org/licenses/by/4.0/